Pharma Mar S.A. Asset Resilience Ratio
Pharma Mar S.A. asset resilience ratio. Pharma Mar S.A. (PHM) has an Asset Resilience Ratio of 37.82% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Pharma Mar S.A. fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pharma Mar S.A. (2004–2025)
Asset resilience ratio of Pharma Mar S.A. from 2004 to 2025. This chart shows how Pharma Mar S.A.'s Asset Resilience Ratio has changed over time. Read Pharma Mar S.A. debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pharma Mar S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Pharma Mar S.A. asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €149.41 Million | 37.82% |
| Total Liquid Assets | €149.41 Million | 37.82% |
Asset Resilience Insights
- Very High Liquidity: Pharma Mar S.A. maintains exceptional liquid asset reserves at 37.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pharma Mar S.A. Industry Peers by Asset Resilience Ratio
Compare Pharma Mar S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Pharma Mar S.A. Asset Resilience Ratio by Year (2004–2025)
Pharma Mar S.A. asset resilience ratio by year from 2004 to 2025. The table below shows the annual Asset Resilience Ratio data for Pharma Mar S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.82% | €149.41 Million ≈ $174.67 Million |
€395.08 Million ≈ $461.89 Million |
+11.71pp |
| 2024-12-31 | 26.11% | €91.29 Million ≈ $106.73 Million |
€349.64 Million ≈ $408.77 Million |
-4.00pp |
| 2023-12-31 | 30.11% | €102.54 Million ≈ $119.88 Million |
€340.52 Million ≈ $398.10 Million |
+14.67pp |
| 2022-12-31 | 15.44% | €60.73 Million ≈ $71.00 Million |
€393.26 Million ≈ $459.76 Million |
-8.59pp |
| 2021-12-31 | 24.03% | €88.53 Million ≈ $103.50 Million |
€368.39 Million ≈ $430.68 Million |
-6.04pp |
| 2020-12-31 | 30.07% | €99.31 Million ≈ $116.10 Million |
€330.26 Million ≈ $386.11 Million |
+27.46pp |
| 2019-12-31 | 2.61% | €3.26 Million ≈ $3.81 Million |
€124.70 Million ≈ $145.79 Million |
-0.01pp |
| 2018-12-31 | 2.62% | €4.13 Million ≈ $4.83 Million |
€157.68 Million ≈ $184.34 Million |
-1.47pp |
| 2017-12-31 | 4.09% | €7.67 Million ≈ $8.97 Million |
€187.72 Million ≈ $219.46 Million |
-4.09pp |
| 2016-12-31 | 8.17% | €18.08 Million ≈ $21.13 Million |
€221.14 Million ≈ $258.53 Million |
-9.75pp |
| 2015-12-31 | 17.93% | €38.00 Million ≈ $44.42 Million |
€211.94 Million ≈ $247.78 Million |
+8.51pp |
| 2014-12-31 | 9.41% | €18.96 Million ≈ $22.17 Million |
€201.39 Million ≈ $235.44 Million |
+6.05pp |
| 2013-12-31 | 3.37% | €6.38 Million ≈ $7.46 Million |
€189.37 Million ≈ $221.39 Million |
-4.69pp |
| 2012-12-31 | 8.05% | €16.09 Million ≈ $18.81 Million |
€199.83 Million ≈ $233.62 Million |
-0.64pp |
| 2011-12-31 | 8.70% | €18.94 Million ≈ $22.15 Million |
€217.82 Million ≈ $254.65 Million |
-2.56pp |
| 2010-12-31 | 11.26% | €25.98 Million ≈ $30.38 Million |
€230.82 Million ≈ $269.86 Million |
-53.90pp |
| 2005-12-31 | 65.16% | €256.54 Million ≈ $299.92 Million |
€393.72 Million ≈ $460.30 Million |
+6.03pp |
| 2004-12-31 | 59.13% | €199.46 Million ≈ $233.19 Million |
€337.34 Million ≈ $394.38 Million |
-- |
About Pharma Mar S.A.
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound deri… Read more